Medtronic reports Q4 FY24 revenue $8.59B, organic growth 5.4%; FY25 EPS guidance $5.40-$5.50

Medtronic plc

2024-FY EPS reported $2.76 revenue$32,364,000,000

Q4 GAAP diluted EPS $0.49, non-GAAP $1.46; FY24 GAAP diluted EPS $2.76, non-GAAP $5.20.
FY24 revenue $32.4B (+3.6% reported, +5.2% organic); Q4 revenue $8.59B (+0.5% reported, +5.4% organic).
FY25 guidance: organic revenue growth 4%-5%; non-GAAP EPS $5.40-$5.50 (4-6% growth).
Dividend increased to $0.70 quarterly ($2.80 annual), 47th consecutive year of dividend increase.
Broad-based organic growth: Neuroscience +6.5%, Cardiovascular +4.0%, Medical Surgical +4.5%, Diabetes +11.1% in Q4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.